Citadel Advisors
NRIX icon

Citadel Advisors’s Nurix Therapeutics NRIX Stock Holding History

Citadel Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,300
Closed -$104K – 13632
2025
Q3 		$104K Hold
11,300
– – ﹤0.01% 11829
2025
Q2 		$129K Buy
11,300
+3,400
+43% +$36.7K ﹤0.01% 11102
2025
Q1 		$93.9K Sell
7,900
-1,800
-19% -$30.1K ﹤0.01% 11562
2024
Q4 		$183K Sell
9,700
-700
-7% -$16K ﹤0.01% 10592
2024
Q3 		$234K Sell
10,400
-25,700
-71% -$582K ﹤0.01% 9834
2024
Q2 		$753K Buy
36,100
+31,800
+740% +$495K ﹤0.01% 7186
2024
Q1 		$63.2K Sell
4,300
-1,600
-27% -$17.2K ﹤0.01% 11939
2023
Q4 		$60.9K Sell
5,900
-5,300
-47% -$36.3K ﹤0.01% 11577
2023
Q3 		$88K Sell
11,200
-1,100
-9% -$10K ﹤0.01% 11051
2023
Q2 		$123K Buy
12,300
+10,200
+486% +$104K ﹤0.01% 10615
2023
Q1 		$18.6K Buy
2,100
+1,600
+320% +$16.7K ﹤0.01% 13116
2022
Q4 		$5.49K Buy
+500
New +$6.03K ﹤0.01% 13992

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Citadel Advisors's NRIX Position: Q1 2026 in Review

Citadel Advisors increased its Nurix Therapeutics (NRIX) stake by 17% in Q1 2026, buying an estimated $3.16M and bringing the position to 1,343,700 shares worth $20.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2295.

Citadel Advisors first reported a position in NRIX in Q3 2020 and has held it in 21 quarters since. The position peaked at $34.4M in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Citadel Advisors held 1,343,700 shares of Nurix Therapeutics worth $20.8M as of Q1 2026.
  • Citadel Advisors bought 190,770 Nurix Therapeutics shares in Q1 2026, an estimated $3.16M.
  • Nurix Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2295 holding.
  • Citadel Advisors first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Citadel Advisors's Nurix Therapeutics position peaked at $34.4M in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.